ASCO 2015

29 May–02 June 2015 | Chicago, Illinois

ASCO 2015

29 May–02 June 2015 | Chicago, Illinois
Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma 3:27
Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma
Jeremy Abramson • 2 Jun 2015
A review of current and future directions of clinical trials for CLL 4:03
A review of current and future directions of clinical trials for CLL
Jeremy Abramson • 2 Jun 2015
Advances in the management of follicular lymphoma in the frontline and relapsed settings 3:37
Advances in the management of follicular lymphoma in the frontline and relapsed settings
Jeremy Abramson • 2 Jun 2015
Recent developments in targeted therapies for chronic lymphocytic leukemia 1:47
Recent developments in targeted therapies for chronic lymphocytic leukemia
Jacqueline Barrientos • 2 Jun 2015
HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia 2:00
HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia
Jacqueline Barrientos • 2 Jun 2015
Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL 0:52
Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL
Jacqueline Barrientos
Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL 1:55
Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL
Jacqueline Barrientos
Design and results of pacritinib for myelofibrosis trial (PERSIST-1) 1:45
Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
Jean-Jacques Kiladjian • 2 Jun 2015
Results for the follow-up of the RESPONSE study 1:46
Results for the follow-up of the RESPONSE study
Jean-Jacques Kiladjian • 2 Jun 2015
Design and results of PERSIST-1 trial of pacritinib for myelofibrosis 2:04
Design and results of PERSIST-1 trial of pacritinib for myelofibrosis
Ruben Mesa • 2 Jun 2015
Study design for PERSIST-2 and other upcoming trials of pacritinib 0:54
Study design for PERSIST-2 and other upcoming trials of pacritinib
Ruben Mesa • 2 Jun 2015
Results of ELOQUENT-2 trial for treatment multiple myeloma 2:00
Results of ELOQUENT-2 trial for treatment multiple myeloma
Joseph Mikhael • 2 Jun 2015
Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma 2:01
Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma
Joseph Mikhael • 2 Jun 2015
Results of the phase 2 trial of daratumumab in multiple myeloma 2:03
Results of the phase 2 trial of daratumumab in multiple myeloma
Joseph Mikhael • 2 Jun 2015
Single-agent daratumumab activity in refractory multiple myeloma 3:00
Single-agent daratumumab activity in refractory multiple myeloma
Maria-Victoria Mateos • 2 Jun 2015
Advances in the treatment of CLL at ASCO 2015 3:23
Advances in the treatment of CLL at ASCO 2015
Stephan Stilgenbauer • 2 Jun 2015
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals